| Address:
|
12390 EL CAMINO REAL
SUITE 150 |
| City: |
SAN DIEGO |
|
State: |
CA |
|
Zip Code: |
92130 |
| Telephone: |
858-552-0866 |
|
Description of Business
|
Primary SIC Code:
2834 |
| (As filed with the SEC)
|
|
|
We are a specialty pharmaceutical company focused on acquiring, developing and
commercializing proprietary product candidates. We have not yet marketed or sold
any products or generated any significant revenue.
Our lead product candidates, ExelbineT (vinorelbine injectable emulsion), or
ANX-530, and ANX-514 (docetaxel emulsion for injection), are novel emulsion
formulations of currently marketed chemotherapy drugs. We believe Exelbine and
ANX-514 may improve the safety of the currently marketed reference products,
Navelbine® (vinorelbine tartrate) Injection and Taxotere® (docetaxel) Injection
Concentrate, respectively.
In November 2010, we submitted a new drug application, or NDA, for Exelbine to
the U.S. Food and Drug Administration, or FDA, and in January 2011, we announced
that the FDA accepted the Exelbine NDA for filing and established a Prescription
Drug User Fee Act, or PDUFA, goal date of September 1, 2011 to finish its review
of the Exelbine NDA. ... More ... |
| Date |
12-mos
Rolling EPS |
Dividend |
P/E
Ratio |
| 09/2011 | -0.56 | NA | N/E | | 06/2011 | -0.51 | NA | N/E | | 03/2011 | -0.72 | NA | N/E | | 12/2010 | -1.07 | NA | N/E | | 09/2010 | -2.04 | NA | N/E | | 06/2010 | -2.46 | NA | N/E | | 03/2010 | -77.75 | NA | N/E | | 12/2009 | -87.50 | NA | N/E |
Key Financial Ratios and Statistics |
FYE:
12/31 |
| Profitability |
2010 |
Leverage |
2010 |
| Net Inc/Comm Equity | -0.05 | Total Liab/Total Assets | 0.06 | | Net Inc/Total Assets | -0.30 | Total Liab/Inv Cap | 0.07 | | Net Inc/Inv Cap | -0.32 | Total Liab/Comm Equity | 0.01 | | Pretax Inc/Net Sales | -17.28 | Interest Coverage Ratio | -5186.80 | | Net Inc/Net Sales | -17.28 | Curr Debt/Equity | NA | | Cash Flow/Net Sales | -17.06 | LTD/Equity | NA | | SG&A/NetSales | 10.88 | Total Debt/Equity | NA |
| Asset Utilization
|
|
Liquidity |
|
| Net Receivables Turnover | 58.14 | Quick Ratio | 15.77 | | Inventory Turnover | NA | Current Ratio | 15.77 | | Inventory Day Sales | NA | Net Rec/Curr Assets | 0.00 | | Net Sales/Work Cap | 0.02 | Inv/Curr Assets | NA | | Net Sales/PP&E | 11.05 | | |
Income Statement (Millions) |
| |
9/30/2011
|
6/30/2011
|
3/31/2011
|
12/31/2010
|
|
Total Revenues(Net Sales)
|
0.00
|
0.00
|
0.00
|
0.49
|
|
Cost of Goods Sold
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Selling & Admin Exps
|
1.49
|
3.05
|
2.37
|
1.90
|
|
Operating Income
|
-3.55
|
-4.41
|
-2.99
|
-2.31
|
|
Interest Exp
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Pretax Income
|
-3.54
|
-4.39
|
-2.96
|
-2.28
|
|
Other Income
|
0.01
|
0.01
|
0.04
|
0.02
|
|
Net Income Bef Extraordinary ...
|
NA
|
NA
|
NA
|
NA
|
|
Net Income
|
-3.54
|
-4.39
|
-2.96
|
-2.28
|
|
Assets
|
9/30/2011
|
6/30/2011
|
3/31/2011
|
12/31/2010
|
|
Cash & Short Term Investments
|
38.29
|
41.96
|
46.55
|
27.98
|
|
Receivables - Total
|
0.01
|
0.00
|
0.00
|
0.00
|
|
Inventories - Total
|
NA
|
NA
|
NA
|
NA
|
|
Total Current Assets
|
39.04
|
42.73
|
46.89
|
28.41
|
|
Net Property, Plant & Equipment
|
0.24
|
0.06
|
0.04
|
0.04
|
|
Total Assets
|
46.27
|
50.16
|
46.96
|
28.49
|
|
Liabilities
|
|
|
|
|
|
Accounts Payable
|
2.48
|
2.36
|
2.13
|
1.80
|
|
Debt in Current Liabilities
|
NA
|
NA
|
NA
|
NA
|
|
Total Current Liabilities
|
3.12
|
2.36
|
2.13
|
1.80
|
|
Long-Term Debt
|
NA
|
NA
|
NA
|
NA
|
|
Total Liabilities
|
3.12
|
3.76
|
2.13
|
1.80
|
|
Stockholder's Equity
|
|
|
|
|
|
Minority Interest
|
NA
|
NA
|
NA
|
NA
|
|
Preferred Stock
|
NA
|
NA
|
NA
|
0.00
|
|
Common Stock
|
0.03
|
0.03
|
0.02
|
0.02
|
|
Retained Earnings
|
-167.02
|
-163.48
|
-159.09
|
-156.13
|
|
Treasury Stock
|
NA
|
NA
|
NA
|
NA
|
|
Total Stockholders' Equity
|
43.15
|
46.40
|
44.82
|
26.69
|
|
Total Liabilities and Stockholders' Equity
|
46.27
|
50.16
|
46.96
|
28.49
|
Cash Flow Summary (Millions) |
|
Categories
|
9/30/2011
|
6/30/2011
|
3/31/2011
|
12/31/2010
|
|
Net Cash Provided by Operating Activities
|
-3.45
|
-4.59
|
-2.38
|
-1.33
|
|
Net Cash Provided by Investing Activities
|
-5.71
|
-0.01
|
-0.00
|
-0.02
|
|
Net Cash Provided by Financing Activities
|
0.00
|
0.00
|
20.96
|
-0.00
|
Annual Summary Data (Millions) |
| Year |
Sales |
Net
Income |
EPS |
| 12/2006 | 0.00 | -29.33 | -- | | 12/2007 | 0.50 | -22.14 | -- | | 12/2008 | 0.50 | -26.65 | -- | | 12/2009 | 0.30 | -11.33 | -87.50 | | 12/2010 | 0.49 | -8.45 | -1.07 | | Growth Rates | Infinity | -- | -- |
| Type |
Date(Q,M) |
No.
Owners |
Shares
Held (000s) |
%
Own |
| Institutional | 12/31/11 | 30 | 3,932 | 8.24 |
|
Report Date :
1/30/2012
 Copyright
2012, EDGAR Online, Inc. All
rights reserved. Replication or redistribution of EDGAR Online, Inc. content is
expressly prohibited without the prior written consent of EDGAR Online, Inc.
EDGAR Online, Inc. shall not be liable for any errors or delays in the content,
or for any actions taken in reliance thereon.
|
|
|